Menu

Pharmaceuticals

MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies

, , ,

January 8, 2014 – AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an oncology research collaboration and licensing agreement with Immunocore Limited, a privately-held, UK-based biotechnology company. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology. This platform […]

Crystal Bioscience and Boehringer Ingelheim Announce Multiple Target Antibody Discovery Collaboration

, , ,

EMERYVILLE, CA and INGELHEIM, Germany, 7 January – Crystal Bioscience Inc. (Crystal) and Boehringer Ingelheim announced today that they have entered into an agreement to collaborate on the discovery and development of therapeutic antibodies. Crystal Bioscience will apply its proprietary gel encapsulated microenvironment (GEM) and chicken immunization platforms to discover antibodies to multiple targets selected by […]

Gilead Sciences’ Kevin Young CBE, Executive Vice President, Commercial Operations, to Retire

, , ,

FOSTER CITY, Calif.–(BUSINESS WIRE)–Jan. 6, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Kevin Young CBE, Executive Vice President, Commercial Operations, has informed the company of his decision to retire, effective February 4th. Mr. Young will continue to work directly with Gilead’s management team as a senior advisor. Mr. Young joined Gilead in 2004 to lead the company’s global commercial […]

Intercept Pharmaceuticals to Provide 2013 Update on Clinical Programs for Obeticholic Acid on January 9

, ,

NEW YORK, Jan. 2, 2014 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that it will provide an update on the progress of its clinical development programs after theNASDAQ Market closes on January 9, 2014. This update will […]

Rakesh Bamzai Joins Mylan as President, India Commercial and Emerging Markets

, , ,

PITTSBURGH, Jan. 2, 2014 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that Rakesh Bamzai has joined the company and has been appointed president, India Commercial and Emerging Markets. Bamzai has more than 20 years of experience in the Indian and global biopharmaceutical industry. Prior to joining Mylan, he was president of Marketing at Biocon, […]

AstraZeneca and Shionogi settle arbitration and extend licence agreement for CRESTOR®

, , ,

December 26, 2013 – AstraZeneca and Shionogi & Co. Ltd. today announced the full resolution of arbitration proceedings related to the treatment of certain excise taxes and other specific items in the calculation of royalties on CRESTOR® sales. In addition, AstraZeneca and Shionogi & Co. Ltd. announced the extension of the global licence agreement for CRESTOR® […]

FDA Approves Orenitram™ (treprostinil) Extended-Release Tablets for the Treatment of Pulmonary Arterial Hypertension

, ,

Conference Call to be Held at 9:00 a.m. Eastern Time, December 23, 2013 SILVER SPRING, Md., Dec. 20, 2013 /PRNewswire/ — United Therapeutics Corporation (NASDAQ: UTHR) announced today that the United States Food and Drug Administration (FDA) has approved Orenitram (treprostinil) Extended-Release Tablets for the treatment of pulmonary arterial hypertension (PAH) in WHO Group I patients to improve exercise capacity. “This […]

Roche’s new subcutaneous formulation of RoACTEMRA gains CHMP positive opinion in Europe for moderate to severe rheumatoid arthritis

, , ,

Upon approval, RoACTEMRA would be the first IL-6 biologic available in subcutaneous and intravenous administration for both monotherapy and combination therapy New subcutaneous formulation would offer greater flexibility for rheumatoid arthritis patients Basel, 20 December 2013 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the subcutaneous formulation of RoACTEMRA (tocilizumab) has received a positive […]

Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product

, , , , ,

New Drug Application follows submission of Marketing Authorisation Application to the European Medicines Agency INDIANAPOLIS and RIDGEFIELD, Conn., Dec. 20, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for LY2963016, an […]

Study Shows Robotic-Assisted Prostate Surgery Reduces Hospital Readmission and Complication Rates Compared to Open Surgery

, , , , ,

Highlights Impact on Cost of Care SUNNYVALE, Calif., Dec. 19, 2013 (GLOBE NEWSWIRE) — A national, multi-institutional database study found readmission and complication rates were significantly lower for robotic-assisted prostate surgery than for open prostate surgery.1 The full study results were published in the November 19 electronic edition of the Journal of Endourology. “Readmissions for Medicare patients alone currently add $17.4 billion each year in […]

«‹ 18 19 20 21›»